1014 related articles for article (PubMed ID: 29382307)
21. Performance of Candidate Serum Biomarkers for Systemic Sclerosis-Associated Interstitial Lung Disease.
Elhai M; Hoffmann-Vold AM; Avouac J; Pezet S; Cauvet A; Leblond A; Fretheim H; Garen T; Kuwana M; Molberg Ø; Allanore Y
Arthritis Rheumatol; 2019 Jun; 71(6):972-982. PubMed ID: 30624031
[TBL] [Abstract][Full Text] [Related]
22. Prediction of progression of interstitial lung disease in patients with systemic sclerosis: the SPAR model.
Wu W; Jordan S; Becker MO; Dobrota R; Maurer B; Fretheim H; Ye S; Siegert E; Allanore Y; Hoffmann-Vold AM; Distler O
Ann Rheum Dis; 2018 Sep; 77(9):1326-1332. PubMed ID: 29875097
[TBL] [Abstract][Full Text] [Related]
23. Quantifying change in pulmonary function as a prognostic marker in systemic sclerosis-related interstitial lung disease.
Moore OA; Proudman SM; Goh N; Corte TJ; Rouse H; Hennessy O; Morrisroe K; Thakkar V; Sahhar J; Roddy J; Youssef P; Gabbay E; Nash P; Zochling J; Stevens W; Nikpour M
Clin Exp Rheumatol; 2015; 33(4 Suppl 91):S111-6. PubMed ID: 26243401
[TBL] [Abstract][Full Text] [Related]
24. Quantitative computed tomography assessment for systemic sclerosis-related interstitial lung disease: comparison of different methods.
Ufuk F; Demirci M; Altinisik G
Eur Radiol; 2020 Aug; 30(8):4369-4380. PubMed ID: 32193641
[TBL] [Abstract][Full Text] [Related]
25. Does Systemic Sclerosis-associated Interstitial Lung Disease Burn Out? Specific Phenotypes of Disease Progression.
Guler SA; Winstone TA; Murphy D; Hague C; Soon J; Sulaiman N; Li KH; Dunne J; Wilcox PG; Ryerson CJ
Ann Am Thorac Soc; 2018 Dec; 15(12):1427-1433. PubMed ID: 30188737
[TBL] [Abstract][Full Text] [Related]
26. Clinical Features of Idiopathic Interstitial Pneumonia with Systemic Sclerosis-Related Autoantibody in Comparison with Interstitial Pneumonia with Systemic Sclerosis.
Yamakawa H; Hagiwara E; Kitamura H; Yamanaka Y; Ikeda S; Sekine A; Baba T; Iso S; Okudela K; Iwasawa T; Takemura T; Kuwano K; Ogura T
PLoS One; 2016; 11(8):e0161908. PubMed ID: 27564852
[TBL] [Abstract][Full Text] [Related]
27. Interstitial lung disease in systemic sclerosis: data from the spanish scleroderma study group.
Sánchez-Cano D; Ortego-Centeno N; Callejas JL; Fonollosa Plá V; Ríos-Fernández R; Tolosa-Vilella C; Espinosa-Garriga G; Colunga-Argüelles D; Egurbide-Arberas MV; Rubio-Rivas M; Freire M; Ríos-Blanco JJ; Trapiella-Martínez L; Rodríguez-Carballeira M; Marín-Ballvé A; Pla-Salas X; Simeón-Aznar CP
Rheumatol Int; 2018 Mar; 38(3):363-374. PubMed ID: 29322341
[TBL] [Abstract][Full Text] [Related]
28. Hemodynamic Response to Treatment and Outcomes in Pulmonary Hypertension Associated With Interstitial Lung Disease Versus Pulmonary Arterial Hypertension in Systemic Sclerosis: Data From a Study Identifying Prognostic Factors in Pulmonary Hypertension Associated With Interstitial Lung Disease.
Chauvelot L; Gamondes D; Berthiller J; Nieves A; Renard S; Catella-Chatron J; Ahmad K; Bertoletti L; Camara B; Gomez E; Launay D; Montani D; Mornex JF; Prévot G; Sanchez O; Schott AM; Subtil F; Traclet J; Turquier S; Zeghmar S; Habib G; Reynaud-Gaubert M; Humbert M; Cottin V
Arthritis Rheumatol; 2021 Feb; 73(2):295-304. PubMed ID: 32892515
[TBL] [Abstract][Full Text] [Related]
29. Comparison of clinical courses and mortality of connective tissue disease-associated interstitial pneumonias and chronic fibrosing idiopathic interstitial pneumonias.
Yıldırım F; Türk M; Bitik B; Erbaş G; Köktürk N; Haznedaroğlu Ş; Türktaş H
Kaohsiung J Med Sci; 2019 Jun; 35(6):365-372. PubMed ID: 30913371
[TBL] [Abstract][Full Text] [Related]
30. Interstitial lung disease increases mortality in systemic sclerosis patients with pulmonary arterial hypertension without affecting hemodynamics and exercise capacity.
Michelfelder M; Becker M; Riedlinger A; Siegert E; Drömann D; Yu X; Petersen F; Riemekasten G
Clin Rheumatol; 2017 Feb; 36(2):381-390. PubMed ID: 28028682
[TBL] [Abstract][Full Text] [Related]
31. Fast 1.5 T chest MRI for the assessment of interstitial lung disease extent secondary to systemic sclerosis.
Pinal-Fernandez I; Pineda-Sanchez V; Pallisa-Nuñez E; Simeon-Aznar CP; Selva-O'Callaghan A; Fonollosa-Pla V; Vilardell-Tarres M
Clin Rheumatol; 2016 Sep; 35(9):2339-45. PubMed ID: 27107755
[TBL] [Abstract][Full Text] [Related]
32. Pleural irregularity, a new ultrasound sign for the study of interstitial lung disease in systemic sclerosis and antisynthetase syndrome.
Pinal-Fernandez I; Pallisa-Nuñez E; Selva-O'Callaghan A; Castella-Fierro E; Simeon-Aznar CP; Fonollosa-Pla V; Vilardell-Tarres M
Clin Exp Rheumatol; 2015; 33(4 Suppl 91):S136-41. PubMed ID: 26315813
[TBL] [Abstract][Full Text] [Related]
33. Interleukin-17 and interleukin-23: importance in the pathogenesis of lung impairment in patients with systemic sclerosis.
Olewicz-Gawlik A; Danczak-Pazdrowska A; Kuznar-Kaminska B; Gornowicz-Porowska J; Katulska K; Trzybulska D; Batura-Gabryel H; Silny W; Poplawski D; Hrycaj P
Int J Rheum Dis; 2014 Jul; 17(6):664-70. PubMed ID: 24467649
[TBL] [Abstract][Full Text] [Related]
34. Pericardial abnormalities predict the presence of echocardiographically defined pulmonary arterial hypertension in systemic sclerosis-related interstitial lung disease.
Fischer A; Misumi S; Curran-Everett D; Meehan RT; Ulrich SK; Swigris JJ; Frankel SK; Cosgrove GP; Lynch DA; Brown KK
Chest; 2007 Apr; 131(4):988-92. PubMed ID: 17426200
[TBL] [Abstract][Full Text] [Related]
35. Ventilation distribution as a contributor to the functional exercise capacity in patients with systemic sclerosis-associated interstitial lung disease without pulmonary hypertension.
Andrade FM; Oliveira AD; Lopes AJ
Braz J Med Biol Res; 2019; 52(8):e8513. PubMed ID: 31365695
[TBL] [Abstract][Full Text] [Related]
36. Respiratory bronchiolitis with fibrosis. High-resolution computed tomography findings and correlation with pathology.
Reddy TL; Mayo J; Churg A
Ann Am Thorac Soc; 2013 Dec; 10(6):590-601. PubMed ID: 24024643
[TBL] [Abstract][Full Text] [Related]
37. Longitudinal Changes in Quantitative Interstitial Lung Disease on Computed Tomography after Immunosuppression in the Scleroderma Lung Study II.
Goldin JG; Kim GHJ; Tseng CH; Volkmann E; Furst D; Clements P; Brown M; Roth M; Khanna D; Tashkin DP
Ann Am Thorac Soc; 2018 Nov; 15(11):1286-1295. PubMed ID: 30265153
[TBL] [Abstract][Full Text] [Related]
38. Short-Term Pulmonary Function Trends Are Predictive of Mortality in Interstitial Lung Disease Associated With Systemic Sclerosis.
Goh NS; Hoyles RK; Denton CP; Hansell DM; Renzoni EA; Maher TM; Nicholson AG; Wells AU
Arthritis Rheumatol; 2017 Aug; 69(8):1670-1678. PubMed ID: 28426895
[TBL] [Abstract][Full Text] [Related]
39. Severity and features of frailty in systemic sclerosis-associated interstitial lung disease.
Guler SA; Kwan JM; Winstone TA; Milne KM; Dunne JV; Wilcox PG; Ryerson CJ
Respir Med; 2017 Aug; 129():1-7. PubMed ID: 28732817
[TBL] [Abstract][Full Text] [Related]
40. Intravenous cyclophosphamide pulse therapy in interstitial lung disease associated with systemic sclerosis in a retrospective open-label study: influence of the extent of inflammation on pulmonary function.
van den Hombergh WMT; Simons SO; Teesselink E; Knaapen-Hans HKA; van den Hoogen FHJ; Fransen J; Vonk MC
Clin Rheumatol; 2018 Oct; 37(10):2715-2722. PubMed ID: 29987427
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]